NO319048B1 - Kombinasjonspreparat av endotelinantagonist og beta-reseptorblokker, fremgangsmate for fremstilling derav samt anvendelse derav for behandling av sykdommer. - Google Patents

Kombinasjonspreparat av endotelinantagonist og beta-reseptorblokker, fremgangsmate for fremstilling derav samt anvendelse derav for behandling av sykdommer. Download PDF

Info

Publication number: NO319048B1
Authority: NO; Norway
Prior art keywords: preparation; beta; combination; endothelin antagonist; diseases
Prior art date: 1997-09-30

Application number

NO20001634A

Other languages

English (en)

Norwegian (no)

Other versions

NO20001634D0 (no

NO20001634L (no

Inventor

Michael Kirchengast

Klaus Muenter

Original Assignee

Abbott Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-30

Filing date

2000-03-29

Publication date

2005-06-06

2000-03-29 Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg

2000-03-29 Publication of NO20001634D0 publication Critical patent/NO20001634D0/no

2000-03-29 Publication of NO20001634L publication Critical patent/NO20001634L/no

2005-06-06 Publication of NO319048B1 publication Critical patent/NO319048B1/no

Links

239000002876 beta blocker Substances 0.000 title claims abstract description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 11
201000010099 disease Diseases 0.000 title claims abstract description 8
239000002308 endothelin receptor antagonist Substances 0.000 title claims description 13
238000002360 preparation method Methods 0.000 title claims description 11
238000000034 method Methods 0.000 title description 2
239000005557 antagonist Substances 0.000 claims abstract description 6
206010047139 Vasoconstriction Diseases 0.000 claims description 10
230000025033 vasoconstriction Effects 0.000 claims description 10
239000000825 pharmaceutical preparation Substances 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
239000001301 oxygen Substances 0.000 claims description 3
230000001575 pathological effect Effects 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical group O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 claims 1
FEJVSJIALLTFRP-LJQANCHMSA-N darusentan Chemical compound COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 FEJVSJIALLTFRP-LJQANCHMSA-N 0.000 claims 1
102000002045 Endothelin Human genes 0.000 abstract description 6
108050009340 Endothelin Proteins 0.000 abstract description 6
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract description 6
150000001875 compounds Chemical class 0.000 description 7
FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 description 6
229950005341 bucindolol Drugs 0.000 description 6
239000007903 gelatin capsule Substances 0.000 description 6
229940126062 Compound A Drugs 0.000 description 5
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
239000000654 additive Substances 0.000 description 5
125000000217 alkyl group Chemical group 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
229920005862 polyol Polymers 0.000 description 4
150000003077 polyols Chemical class 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000008298 dragée Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000007940 sugar coated tablet Substances 0.000 description 3
206010019280 Heart failures Diseases 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010063897 Renal ischaemia Diseases 0.000 description 2
239000003925 fat Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
208000031225 myocardial ischemia Diseases 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
-1 tetratolol Chemical compound 0.000 description 2
239000002966 varnish Substances 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000001993 wax Substances 0.000 description 2
CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
102000005862 Angiotensin II Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
102000017914 EDNRA Human genes 0.000 description 1
108010090549 Endothelin A Receptor Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
208000000558 Varicose Ulcer Diseases 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
229960002122 acebutolol Drugs 0.000 description 1
GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
229960002213 alprenolol Drugs 0.000 description 1
PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229960002781 bisoprolol Drugs 0.000 description 1
VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
229960001035 bopindolol Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229960000330 bupranolol Drugs 0.000 description 1
HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
BQXQGZPYHWWCEB-UHFFFAOYSA-N carazolol Chemical compound N1C2=CC=CC=C2C2=C1C=CC=C2OCC(O)CNC(C)C BQXQGZPYHWWCEB-UHFFFAOYSA-N 0.000 description 1
229960004634 carazolol Drugs 0.000 description 1
229960001222 carteolol Drugs 0.000 description 1
LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
229960004195 carvedilol Drugs 0.000 description 1
NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
229960002320 celiprolol Drugs 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229960003745 esmolol Drugs 0.000 description 1
AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
239000003906 humectant Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
229960003134 mepindolol Drugs 0.000 description 1
229960002704 metipranolol Drugs 0.000 description 1
BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 description 1
229960002237 metoprolol Drugs 0.000 description 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
229960004255 nadolol Drugs 0.000 description 1
VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000006259 organic additive Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229960004570 oxprenolol Drugs 0.000 description 1
229960002035 penbutolol Drugs 0.000 description 1
KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
229960002508 pindolol Drugs 0.000 description 1
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229960002370 sotalol Drugs 0.000 description 1
ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960003658 talinolol Drugs 0.000 description 1
MXFWWQICDIZSOA-UHFFFAOYSA-N talinolol Chemical compound C1=CC(OCC(O)CNC(C)(C)C)=CC=C1NC(=O)NC1CCCCC1 MXFWWQICDIZSOA-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

NO20001634A 1997-09-30 2000-03-29 Kombinasjonspreparat av endotelinantagonist og beta-reseptorblokker, fremgangsmate for fremstilling derav samt anvendelse derav for behandling av sykdommer. NO319048B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19743143A DE19743143A1 (de)	1997-09-30	1997-09-30	Pharmazeutische Kombinationspräparate
PCT/EP1998/005772 WO1999016444A1 (fr)	1997-09-30	1998-09-10	Antagoniste d'endotheline et beta-bloquants sous forme d'association

Publications (3)

Publication Number	Publication Date
NO20001634D0 NO20001634D0 (no)	2000-03-29
NO20001634L NO20001634L (no)	2000-03-29
NO319048B1 true NO319048B1 (no)	2005-06-06

Family

ID=7844115

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20001634A NO319048B1 (no)	1997-09-30	2000-03-29	Kombinasjonspreparat av endotelinantagonist og beta-reseptorblokker, fremgangsmate for fremstilling derav samt anvendelse derav for behandling av sykdommer.

Country Status (16)

Country	Link
US (1)	US6352992B1 (fr)
EP (1)	EP1019055B1 (fr)
JP (1)	JP4608093B2 (fr)
KR (1)	KR100623122B1 (fr)
CN (1)	CN1149087C (fr)
AT (1)	ATE239479T1 (fr)
AU (1)	AU739860B2 (fr)
BR (1)	BR9812404A (fr)
CA (1)	CA2304698C (fr)
CZ (1)	CZ298745B6 (fr)
DE (2)	DE19743143A1 (fr)
ES (1)	ES2199461T3 (fr)
HU (1)	HU226745B1 (fr)
NO (1)	NO319048B1 (fr)
RU (1)	RU2213577C2 (fr)
WO (1)	WO1999016444A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19533023B4 (de) *	1994-10-14	2007-05-16	Basf Ag	Neue Carbonsäurederivate, ihre Herstellung und Verwendung
EP1243262B1 (fr)	2001-03-20	2006-05-31	Schwarz Pharma Ag	Nouvelle utilisation d'un composé peptidique pour le traitement de la douleur inflammatoire non-neuropathique
PT1243263E (pt)	2001-03-21	2003-03-31	Sanol Arznei Schwarz Gmbh	Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
AU2005232395B2 (en)	2004-04-16	2010-09-09	Schwarz Pharma Ag	Use of peptidic compounds for the prophylaxis and treatment of chronic headache
AU2005276634B2 (en)	2004-08-27	2011-03-24	Ucb Pharma Gmbh	Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
RU2389798C2 (ru) *	2004-09-14	2010-05-20	Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт	Способ лечения буциндололом, основанный на определении генотипа
US20070196510A1 (en) *	2006-02-17	2007-08-23	Gerber Michael J	Method for treating resistant hypertension
WO2007144195A2 (fr)	2006-06-15	2007-12-21	Schwarz Pharma Ag	Composition pharmaceutique ayant un effet anticonvulsivant synergique
JP2010536880A (ja)	2007-08-22	2010-12-02	ギリード・コロラド・インコーポレーテッド	糖尿病の合併症のための療法
CN104887645B (zh) *	2015-06-15	2016-12-14	吉林万通药业集团梅河药业股份有限公司	阿莫西林胶囊及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4786441A (en) *	1987-08-24	1988-11-22	International Business Machines Corporation	Preparation of iodonium and sulfonium triflates
SE8704081D0 (sv) *	1987-10-21	1987-10-21	Haessle Ab	A new prohylactic method
DE69422742T2 (de) *	1993-03-19	2000-08-17	Merck & Co., Inc.	Phenoxyphenylessigsäurederivate
GB2300636A (en) *	1994-01-28	1996-11-13	Cal Int Ltd	Pharmaceutical product comprising a salicylate of an esterifiable beta-blocker
DE4411225A1 (de) *	1994-03-31	1995-10-05	Basf Ag	Verwendung von Carbonsäurederivaten als Arzneimittel
DE19533023B4 (de) *	1994-10-14	2007-05-16	Basf Ag	Neue Carbonsäurederivate, ihre Herstellung und Verwendung
MX9703988A (es) *	1994-12-12	1998-02-28	Omeros Med Sys Inc	SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
AU706940B2 (en) *	1995-01-27	1999-07-01	Rhone-Poulenc Rorer Limited	Substituted phenyl compounds as endothelin antagonists
DE19636046A1 (de)	1996-09-05	1998-03-12	Basf Ag	Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
DE19652374A1 (de) *	1996-12-04	1998-06-10	Schering Ag	Verwendung von Endothelin-Konjugaten in der Therapie, neue Endothelin-Konjugate, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
CA2275256A1 (fr) *	1996-12-18	1998-06-25	Basf Aktiengesellschaft	Derives d'acide carboxylique heterocycliques, leur preparation et leur utilisation comme antagonistes du recepteur de l'endotheline

1997
- 1997-09-30 DE DE19743143A patent/DE19743143A1/de not_active Withdrawn
1998
- 1998-09-10 KR KR1020007003346A patent/KR100623122B1/ko not_active Expired - Fee Related
- 1998-09-10 RU RU2000111500/14A patent/RU2213577C2/ru not_active IP Right Cessation
- 1998-09-10 CN CNB988097273A patent/CN1149087C/zh not_active Expired - Fee Related
- 1998-09-10 ES ES98945323T patent/ES2199461T3/es not_active Expired - Lifetime
- 1998-09-10 DE DE59808297T patent/DE59808297D1/de not_active Expired - Lifetime
- 1998-09-10 CA CA002304698A patent/CA2304698C/fr not_active Expired - Fee Related
- 1998-09-10 HU HU0004590A patent/HU226745B1/hu not_active IP Right Cessation
- 1998-09-10 US US09/508,989 patent/US6352992B1/en not_active Expired - Lifetime
- 1998-09-10 BR BR9812404-8A patent/BR9812404A/pt active Search and Examination
- 1998-09-10 AT AT98945323T patent/ATE239479T1/de active
- 1998-09-10 CZ CZ20001081A patent/CZ298745B6/cs not_active IP Right Cessation
- 1998-09-10 EP EP98945323A patent/EP1019055B1/fr not_active Expired - Lifetime
- 1998-09-10 WO PCT/EP1998/005772 patent/WO1999016444A1/fr not_active Ceased
- 1998-09-10 AU AU92672/98A patent/AU739860B2/en not_active Ceased
- 1998-09-10 JP JP2000513580A patent/JP4608093B2/ja not_active Expired - Fee Related
2000
- 2000-03-29 NO NO20001634A patent/NO319048B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUP0004590A3 (en)	2002-01-28
KR20010015650A (ko)	2001-02-26
CN1272786A (zh)	2000-11-08
RU2213577C2 (ru)	2003-10-10
DE19743143A1 (de)	1999-04-01
CZ20001081A3 (en)	2001-05-16
KR100623122B1 (ko)	2006-09-12
US6352992B1 (en)	2002-03-05
AU9267298A (en)	1999-04-23
NO20001634D0 (no)	2000-03-29
DE59808297D1 (de)	2003-06-12
ATE239479T1 (de)	2003-05-15
HUP0004590A2 (hu)	2001-11-28
EP1019055A1 (fr)	2000-07-19
CN1149087C (zh)	2004-05-12
CZ298745B6 (cs)	2008-01-16
HU226745B1 (en)	2009-09-28
BR9812404A (pt)	2000-09-19
JP2001517703A (ja)	2001-10-09
WO1999016444A1 (fr)	1999-04-08
AU739860B2 (en)	2001-10-25
HK1032355A1 (en)	2001-07-20
CA2304698C (fr)	2008-02-19
CA2304698A1 (fr)	1999-04-08
NO20001634L (no)	2000-03-29
EP1019055B1 (fr)	2003-05-07
ES2199461T3 (es)	2004-02-16
JP4608093B2 (ja)	2011-01-05

Legal Events

Date	Code	Title	Description
2014-06-02	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: ABBVIE DEUTSCHLAND GMBH & CO AG, DE
2015-04-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
CA2808912C (fr)	2019-09-17	Formes galeniques a liberation modifiee d'agonistes de 5-ht2c, utiles pour la gestion du poids
EA019471B1 (ru)	2014-03-31	Твердая фармацевтическая композиция, содержащая амлодипин и лозартан
NO319048B1 (no)	2005-06-06	Kombinasjonspreparat av endotelinantagonist og beta-reseptorblokker, fremgangsmate for fremstilling derav samt anvendelse derav for behandling av sykdommer.
ZA200402173B (en)	2005-03-18	Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors.
NO312578B1 (no)	2002-06-03	Farmasöytisk kombinasjonspreparat
JP2009513713A (ja)	2009-04-02	ｐ３８阻害剤化合物による心房細動の治療方法
MX2013005705A (es)	2013-09-16	Tratamiento terapeutico para sindrome metabolico, diabetes tipo 2, obesidad, o prediabetes.
EP4333841A1 (fr)	2024-03-13	2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, inhibiteurs de hdac6 pour utilisation dans le traitement des maladies métaboliques et de l'icfep
US20100311756A1 (en)	2010-12-09	Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
NO325109B1 (no)	2008-02-04	Anvendelse av hydroksylamin-derivater for fremstilling av medisiner for behandling av sykdommer som skyldes skader pa endotelcellene
KR20010086152A (ko)	2001-09-08	특정의 노화 관련 기관의 기능부전과 질병 예방 및 수명연장용 약제를 제조하기 위한 나트륨 수소 교환체억제제의 용도
US20090197916A1 (en)	2009-08-06	Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders
KR20080091366A (ko)	2008-10-10	트리아진 유도체 및 인슐린 분비 자극제의 조합물
US20120135078A1 (en)	2012-05-31	Angina treatment
US20110313006A1 (en)	2011-12-22	PHARMACEUTICAL COMPOSITION OF LEVAMLODIPINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND β RECEPTOR BLOCKING AGENT, AND USE THEREOF
EP2799430B1 (fr)	2016-07-20	Dérivé de diphénylméthyl pipérazine et composition pharmaceutique l'utilisant
Patterson et al.	2003	Expanding Role of β‐Blockade in the Management of Chronic Heart Failure
JP2004002370A (ja)	2004-01-08	重症セプシス予防治療剤
WO2024151866A1 (fr)	2024-07-18	Formulations et méthodes de traitement de la cardiomyopathie hypertrophique
KR100464526B1 (ko)	2005-01-03	나트륨-수소 교환체 타입 1 억제제 결정
MXPA00002654A (en)	2001-05-17	Endothelin antagonist and beta receptor blocking agent as combined preparations
CN120837494A (zh)	2025-10-28	使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
HK1032355B (en)	2005-03-04	Endothelin antagonist and beta receptor blocking agent as combined preparations
CN101415425B (zh)	2014-11-26	甘油三酯降低剂和高胰岛素血症改善剂
WO2005030202A1 (fr)	2005-04-07	Utilisation des antagonistes du recepteur de l'angiotensine ii pour le traitement de troubles cerebrovasculaires